Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (41) 41
humans (38) 38
oncology (28) 28
cancer (27) 27
urothelial carcinoma (27) 27
bladder cancer (24) 24
cell line, tumor (20) 20
urology & nephrology (20) 20
carcinoma (19) 19
chemotherapy (17) 17
bladder-cancer (16) 16
female (16) 16
male (16) 16
aged (15) 15
cisplatin (15) 15
middle aged (15) 15
apoptosis (13) 13
research (13) 13
urinary bladder neoplasms - genetics (13) 13
urinary bladder neoplasms - pathology (12) 12
urology (12) 12
urinary bladder neoplasms - drug therapy (11) 11
urothelial cancer (11) 11
genetic aspects (9) 9
analysis (8) 8
care and treatment (8) 8
health aspects (8) 8
transitional-cell carcinoma (8) 8
urinary bladder neoplasms - metabolism (8) 8
urothelium - pathology (8) 8
aged, 80 and over (7) 7
carcinoma, transitional cell - drug therapy (7) 7
cell survival - drug effects (7) 7
expression (7) 7
histone deacetylase inhibitors - pharmacology (7) 7
metastasis (7) 7
methotrexate (7) 7
prognosis (7) 7
radical cystectomy (7) 7
treatment outcome (7) 7
acetylation (6) 6
biochemistry & molecular biology (6) 6
gemcitabine (6) 6
histone deacetylases - metabolism (6) 6
targeted therapy (6) 6
urologic neoplasms - drug therapy (6) 6
antimitotic agents (5) 5
antineoplastic agents (5) 5
article (5) 5
bladder (5) 5
breast-cancer (5) 5
carcinoma, transitional cell - pathology (5) 5
cell cycle (5) 5
clinical trials (5) 5
gene expression (5) 5
nomogram (5) 5
retrospective studies (5) 5
risk factors (5) 5
therapy (5) 5
trial (5) 5
urinary bladder neoplasms - enzymology (5) 5
urologic neoplasms - pathology (5) 5
urothelium - drug effects (5) 5
adjuvant chemotherapy (4) 4
adult (4) 4
animals (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
biology (4) 4
biomedicine (4) 4
cancer research (4) 4
cell lines (4) 4
cell proliferation - drug effects (4) 4
cells (4) 4
chemistry (4) 4
disease-free survival (4) 4
doxorubicin (4) 4
drug therapy (4) 4
epigenetics (4) 4
flow cytometry (4) 4
gene expression regulation, neoplastic (4) 4
gene knockdown techniques (4) 4
genes (4) 4
genetics (4) 4
germany (4) 4
histone deacetylase (4) 4
histone deacetylase inhibitor (4) 4
histone deacetylases - genetics (4) 4
human bladder-cancer (4) 4
hydroxamic acids - pharmacology (4) 4
mechanisms (4) 4
medicine (4) 4
multicenter (4) 4
oncology, experimental (4) 4
phenotype (4) 4
prognostic factors (4) 4
prostate-cancer (4) 4
proteins (4) 4
survival (4) 4
tumorigenesis (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Beim richtigen Patienten zur richtigen Zeit das richtige Medikament
by Niegisch, Günter
Uro-News, ISSN 1432-9026, 09/2018, Volume 22, Issue 9, pp. 28 - 32
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Aktuelle Systemtherapie des Urothelkarzinoms
by Niegisch, Günter
Aktuelle Urologie, ISSN 0001-7868, 08/2017, Volume 48, Issue 4, pp. 340 - 349
targeted therapy | prognostic factors | urothelial cancer | immune checkpoint inhibition | chemotherapy
Journal Article
Details down arrow
3. Full Text Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
by Droop, Johanna and Szarvas, Tibor and Schulz, Wolfgang A and Niedworok, Christian and Niegisch, GuÈnter and Scheckenbach, Kathrin and Hoffmann, Michèle J
PLoS ONE, ISSN 1932-6203, 04/2017, Volume 12, Issue 4, p. e0176287
Many long noncoding RNAs (lncRNAs) are deregulated in cancer and contribute to oncogenesis. In urothelial carcinoma (UC), several lncRNAs have been reported to... 
ANRIL | BLADDER-CANCER | METASTASIS | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | IDENTIFICATION | TUG1 | UP-REGULATION | CONTRIBUTES | SIGNATURE | CANCER CELL-PROLIFERATION | Cell Line, Tumor | Biomarkers, Tumor - genetics | RNA, Long Noncoding - genetics | Urinary Bladder Neoplasms - genetics | Humans | Urinary Bladder Neoplasms - pathology | Carcinoma | Prognosis | MicroRNA | Physiological aspects | Genetic aspects | Diagnosis | Research | Biological markers | Cancer | Urine | Deregulation | Statistical analysis | Invasiveness | Colorectal cancer | Muscles | Gene expression | Tissues | Medical diagnosis | Patients | Survival | Bladder cancer | Urology | Cell adhesion & migration | Studies | Cell growth | Medical prognosis | Cell lines | Biomarkers | Tumorigenesis | Diagnostic systems | Urothelial carcinoma | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Urothelial cancer: update on systemic treatment options
by Niegisch, G
AKTUELLE UROLOGIE, ISSN 0001-7868, 08/2017, Volume 48, Issue 4, pp. 340 - 349
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern... 
targeted therapy | MULTICENTER | PHASE-III | RANDOMIZED-TRIAL | urothelial cancer | prognostic factors | OPEN-LABEL | chemotherapy | immune checkpoint inhibition | PEMBROLIZUMAB | CISPLATIN | UROLOGY & NEPHROLOGY | CARCINOMA | T-CELLS | PLUS
Journal Article
Details down arrow
5. Full Text Urothelial Carcinoma
: Methods and Protocols
2018, Methods in Molecular Biology, ISBN 9781493972333, Volume 1655
Cancer Research | Biomedicine
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Are bladder cancer patients set at risk by minimally invasive approaches to radical cystectomy?
by Niegisch, Günter
Translational Cancer Research, ISSN 2218-676X, 2017, Volume 6, pp. S221 - S225
Radical cystectomy is the mainstay of surgical treatment in muscle invasive bladder cancer (BC). With the advent of minimally invasive surgical approaches... 
Laparoscopic radical cystectomy | Robotic radical cystectomy | Bladder cancer | Radical cystectomy | SURVIVAL | METAANALYSIS | UROTHELIAL CARCINOMA | CHEMOTHERAPY | ADJUVANT | TRIAL | PERIOPERATIVE OUTCOMES | ONCOLOGY | radical cystectomy | COMPLICATIONS | robotic radical cystectomy | CYSTOPROSTATECTOMY | laparoscopic radical cystectomy | NEOADJUVANT
Journal Article
Details down arrow
7. Full Text HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
by Jaguva Vasudevan, Ananda Ayyappan and Hoffmann, Michèle J and Beck, Michael L C and Poschmann, Gereon and Petzsch, Patrick and Wiek, Constanze and Stühler, Kai and Köhrer, Karl and Schulz, Wolfgang A and Niegisch, Günter
International journal of molecular sciences, ISSN 1422-0067, 04/2019, Volume 20, Issue 9, p. 2135
Class I histone deacetylases (HDACs) generally promote cell proliferation and tumorigenesis, whereas class IIA HDACs like HDAC4 and HDAC5 may promote or impede... 
HDAC4 | HDAC5 | TNFα | proteomics | bladder cancer | transcriptomics | TGFβ | histone deacetylase | EMT | epigenetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
by Knievel, Judith and Schulz, Wolfgang A and Greife, Annemarie and Hader, Christiane and Lübke, Tobias and Schmitz, Ingo and Albers, Peter and Niegisch, Günter
International Journal of Molecular Sciences, ISSN 1661-6596, 09/2014, Volume 15, Issue 11, pp. 20500 - 20517
Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase... 
Mitogen activated protein kinase (MAPK) signaling | Urothelial cancer | Tyrosine kinase inhibitor | Apoptosis | HDAC INHIBITORS | INDUCED APOPTOSIS | URINARY-BLADDER | BIOCHEMISTRY & MOLECULAR BIOLOGY | apoptosis | HEPATOMA-CELLS | urothelial cancer | CHEMISTRY, MULTIDISCIPLINARY | MULTIKINASE INHIBITOR | C-FLIP | tyrosine kinase inhibitor | HUMAN BLADDER-CANCER | mitogen activated protein kinase (MAPK) signaling | BCL-2 FAMILY | CELL-CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Apoptosis - drug effects | Humans | Urinary Bladder Neoplasms - enzymology | Drug Resistance, Neoplasm | Urinary Bladder - pathology | Urinary Bladder Neoplasms - drug therapy | Urothelium - pathology | MAP Kinase Signaling System - drug effects | Urinary Bladder Neoplasms - pathology | Cell Line, Tumor | Urinary Bladder - drug effects | Antineoplastic Agents - pharmacology | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Niacinamide - pharmacology | Urinary Bladder - enzymology | Urothelium - drug effects | Signal transduction | Inhibitor drugs | Kinases | Urogenital system | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
by Hölscher, Alexander S and Schulz, Wolfgang A and Pinkerneil, Maria and Niegisch, Günter and Hoffmann, Michèle J
Clinical Epigenetics, ISSN 1868-7075, 2018, Volume 10, Issue 1, pp. 1 - 14
Background: New efficient therapies for urothelial carcinoma (UC) are urgently required. Small-molecule drugs targeting chromatin regulators are reasonable... 
BET inhibitor | JQ1 | Romidepsin | Bladder cancer | HDACi | Apoptosis | HISTONE DEACETYLASE INHIBITOR | ACTIVATION | MECHANISMS | DEATH | BROMODOMAIN | BREAST-CANCER | ONCOLOGY | BLADDER | EXPRESSION | BRD4 | Cyclin-Dependent Kinase Inhibitor p57 - metabolism | Cell Survival - drug effects | Cyclin-Dependent Kinase Inhibitor p57 - genetics | Humans | Histone Deacetylases - metabolism | Nuclear Proteins - metabolism | Carcinoma, Transitional Cell - metabolism | Depsipeptides - pharmacology | Transcription Factors - genetics | Urinary Bladder Neoplasms - drug therapy | Azepines - pharmacology | Dose-Response Relationship, Drug | Drug Synergism | Transcription Factors - metabolism | Triazoles - pharmacology | Cell Cycle Checkpoints | Carcinoma, Transitional Cell - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Nuclear Proteins - genetics | Urinary Bladder Neoplasms - metabolism | Care and treatment | Carcinoma | Development and progression | Genetic aspects | Genetic transcription | Research | Health aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
by Pinkerneil, Maria and Hoffmann, Michèle J and Kohlhof, Hella and Schulz, Wolfgang A and Niegisch, Günter
Targeted Oncology, ISSN 1776-2596, 12/2016, Volume 11, Issue 6, pp. 783 - 798
Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor... 
Biomedicine, general | Medicine & Public Health | Oncology | PHASE-III TRIAL | MITOSIS | BLADDER-CANCER | CISPLATIN | EFFICACY | ONCOLOGY | ACETYLATION | MECHANISMS | HISTONE DEACETYLASE INHIBITORS | EXPRESSION | CHEMOTHERAPY | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Urinary Bladder Neoplasms - drug therapy | Humans | Immunoglobulin Isotypes - genetics | Carcinoma | Cell death | Health aspects | Analysis | Cancer | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Targeting mTOR in urothelial cancer—Beating a dead horse or ready for prime time?
by Niegisch, Günter and Albers, Peter
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 10/2017, Volume 35, Issue 10, pp. 600 - 601
TOR Serine-Threonine Kinases | Carcinoma, Transitional Cell | Urologic Neoplasms | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
by Lehmann, Maria and Hoffmann, Michèle J and Koch, Annemarie and Ulrich, Scott M and Schulz, Wolfgang A and Niegisch, Günter
Journal of Experimental and Clinical Cancer Research, ISSN 1756-9966, 07/2014, Volume 33, Issue 1
Background: Previous studies have shown that class-I histone deacetylase (HDAC) 8 mRNA is upregulated in urothelial cancer tissues and urothelial cancer cell... 
Cell cycle arrest | Histone deacetylase inhibitor | Histone deacetylase 8 | Urothelial bladder cancer | BLADDER-CANCER | CELLS | APOPTOSIS | HDAC EXPRESSION | ACETYLATION | ONCOLOGY | GASTRIC-CANCER | CLONING | PROSTATE-CANCER | INHIBITORS | CARCINOMA | Research | Comparative analysis | Health aspects | Oncology, Experimental | Cancer | Breast cancer | Kinases | Experiments | Cancer therapies | Bladder cancer | Proteins | Liver cancer | Cell growth | Rodents | Medical prognosis | Cell cycle | Protein expression | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Canonical Notch signalling is inactive in urothelial carcinoma
by Greife, Annemarie and Greife, Annemarie and Jankowiak, Silvia and Jankowiak, Silvia and Steinbring, Jochen and Steinbring, Jochen and Nikpour, Parvaneh and Nikpour, Parvaneh and Niegisch, Günter and Niegisch, Günter and Hoffmann, Michèle J and Hoffmann, Michèle J and Schulz, Wolfgang A and Schulz, Wolfgang A
BMC cancer, ISSN 1471-2407, 2014, Volume 14, Issue 1, pp. 628 - 628
Background: Notch signalling regulates cell fate in most tissues, promoting precursor cell proliferation in some, but differentiation in others. Accordingly,... 
Notch pathway | γ-secretase inhibitors | NOTCH1 | Urothelial carcinoma | Bladder cancer | BLADDER-CANCER | MECHANISM | HES-1 EXPRESSION | gamma-secretase inhibitors | MOLECULAR PATHWAYS | THERAPY | ONCOLOGY | EAU INTERNATIONAL CONSULTATION | SQUAMOUS-CELL CARCINOMA | POLYPLOIDY | LIGAND | MUTATIONS | Cell Proliferation | Receptors, Notch - metabolism | Humans | Middle Aged | Male | Receptors, Notch - genetics | Intercellular Signaling Peptides and Proteins - metabolism | Urinary Bladder Neoplasms - genetics | Serrate-Jagged Proteins | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Female | Membrane Proteins - metabolism | Carcinoma - pathology | Urinary Bladder Neoplasms - metabolism | Calcium-Binding Proteins - metabolism | Tumor Stem Cell Assay | Gene Expression | Signal Transduction | Urinary Bladder - metabolism | Membrane Proteins - genetics | Intercellular Signaling Peptides and Proteins - genetics | Receptor, Notch1 - metabolism | Protein Transport | Cell Line, Tumor | Carcinoma - genetics | Ligands | Aged | Carcinoma - metabolism | Receptor, Notch1 - genetics | Calcium-Binding Proteins - genetics | Cellular signal transduction | Carcinoma | Research | Analysis | Cancer | Urothelium
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text MP52-08 ONCOLOGICAL OUTCOMES, SURGICAL SAFETY AND COMPLICATIONS OF PATIENTS TREATED WITH SPOT SPECIFIC SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE
by Hiester, Andreas and Nini, Alessandro and Niegisch, Günter and Rabenalt, Robert and Albers, Peter
The Journal of Urology, ISSN 0022-5347, 04/2018, Volume 199, Issue 4, pp. e697 - e698
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells
by Heubach, Judith and Monsior, Juliana and Deenen, René and Niegisch, Günter and Szarvas, Tibor and Niedworok, Christian and Schulz, Wolfgang Arthur and Hoffmann, Michèle Janine
Molecular Cancer, ISSN 1476-4598, 05/2015, Volume 14, Issue 1, p. 108
Background: Urothelial carcinoma (UC) is the fifth most common cancer in the developed world. Delineation of differentiation subtypes in UC highlighted the... 
HOTAIR | HOX gene | Long noncoding RNA | Bladder cancer | PROSTATE | STEM-CELLS | METASTASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | LUNG-CANCER | ONCOLOGY | POOR-PROGNOSIS | RECURRENCE | DIFFERENTIATION | HUMAN BLADDER-CANCER | UP-REGULATION | CARCINOMA | Multivariate Analysis | Cell Proliferation | Urothelium - metabolism | Oligonucleotide Array Sequence Analysis | Homeodomain Proteins - metabolism | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Gene Expression Profiling | Urothelium - pathology | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Female | Clone Cells | Neoplasm Invasiveness | Kaplan-Meier Estimate | RNA, Long Noncoding - genetics | Organ Specificity | Homeodomain Proteins - genetics | Phenotype | Cell Line, Tumor | Aged | RNA, Long Noncoding - metabolism | Epigenetic inheritance | Stem cells | Antisense RNA | Genetic aspects | DNA binding proteins | Gene expression | Cell differentiation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
by Niegisch, Günter and Retz, Margitta and Thalgott, Mark and Balabanov, Stefan and Honecker, Friedemann and Ohlmann, Carsten Henning and Stöckle, Michael and Bögemann, Martin and vom Dorp, Frank and Gschwend, Jürgen and Hartmann, Arndt and Ohmann, Christian and Albers, Peter
Oncology, ISSN 0030-2414, 07/2015, Volume 89, Issue 2, pp. 70 - 78
Objective: The efficacy of second-line treatment after failure of platinum-based chemotherapy in patients with advanced urothelial cancer is limited. Based on... 
Clinical Study | Urothelial cancer | Chemotherapy | Platinum failure | Everolimus | Paclitaxel | BLADDER-CANCER | DOXORUBICIN | METHOTREXATE | GEMCITABINE | CISPLATIN | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | EUROPEAN-ORGANIZATION | TRACT TUMORS | PLUS | Humans | Middle Aged | Paclitaxel - adverse effects | Male | Treatment Outcome | Everolimus - administration & dosage | Antineoplastic Agents - administration & dosage | Urothelium - pathology | Urologic Neoplasms - pathology | Urologic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Everolimus - adverse effects | Quality of Life | Adult | Female | Aged | Paclitaxel - administration & dosage | Urothelium - drug effects | Germany | Clinical trials | Urogenital system | Clinical outcomes | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
by Skowron, Margaretha A and Melnikova, Margarita and van Roermund, Joep G. H and Romano, Anea and Albers, Peter and Thomale, Juergen and Schulz, Wolfgang A and Niegisch, Guenter and Hoffmann, Michele J
International Journal of Molecular Sciences, ISSN 1422-0067, 02/2018, Volume 19, Issue 2, p. 590
Therapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and... 
MOLECULAR CHARACTERIZATION | BLADDER-CANCER | BIOMARKER | INDUCED APOPTOSIS | metallothionein | Survivin | resistance mechanisms | CHEMOTHERAPY | CANCER STEM-CELLS | urothelial carcinoma | ENHANCED EXPRESSION | YM155 | cisplatin | DNA-REPAIR | Urothelial carcinoma | Cisplatin | Metallothionein | Resistance mechanisms | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, MULTIDISCIPLINARY | Metallothionein - metabolism | Urothelium - metabolism | Humans | Drug Resistance, Neoplasm | Cisplatin - pharmacology | Cell Cycle | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Carcinoma - metabolism | DNA Damage | Urothelium - drug effects | Urinary Bladder Neoplasms - metabolism | Apoptosis | DNA repair | DNA damage | Deoxyribonucleic acid--DNA | Cell cycle
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Effects of novel HDAC inhibitors on urothelial carcinoma cells
by Kaletsch, Aline and Pinkerneil, Maria and Hoffmann, Michèle J and Jaguva Vasudevan, Ananda A and Wang, Chenyin and Hansen, Finn K and Wiek, Constanze and Hanenberg, Helmut and Gertzen, Christoph and Gohlke, Holger and Kassack, Matthias U and Kurz, Thomas and Schulz, Wolfgang A and Niegisch, Günter
Clinical Epigenetics, ISSN 1868-7075, 07/2018, Volume 10, Issue 1, pp. 100 - 18
Background: Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is... 
Cell cycle arrest | Histone deacetylase inhibitor | Histone deacetylase HDAC4 | Class IIA HDACs | Urothelial bladder cancer | CANCER-CELLS | PHYSIOLOGY | EXPORT | PROFILE | ONCOLOGY | ROLES | CLASS-I | DIFFERENTIATION | EXPRESSION | TUMORIGENESIS | IIA HISTONE DEACETYLASES | Adenocarcinoma | Histones | Care and treatment | Research | Gene expression | Cancer cells | Flow cytometry | Histone deacetylase | Enzymes | Medical research | Chromatin | Senescence | Mitosis | Cytotoxicity | Thymidylate synthase | Bladder cancer | Western blotting | Cyclin-dependent kinase inhibitor p21 | Tubulin | Cell cycle | Cell lines | Acetylation | Urothelial carcinoma | Tumors | Apoptosis | Crystal structure
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Epigenetic treatment options in urothelial carcinoma
by Pinkerneil, Maria and Hoffmann, Michèle J and Niegisch, Günter
Methods in Molecular Biology, ISSN 1064-3745, 2018, Volume 1655, pp. 289 - 317
Mutations, dysregulation, and dysbalance of epigenetic regulators are especially frequent in urothelial carcinoma (UC) compared to other malignancies.... 
Epigenetics | Histone deacetylase inhibitors | Histone deacetylases | Urothelial carcinoma | Targeted therapy | RNA, Small Interfering - genetics | Urologic Neoplasms - diagnosis | Humans | Antineoplastic Agents - therapeutic use | Gene Knockdown Techniques | Dose-Response Relationship, Drug | Caspases - metabolism | Flow Cytometry | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Cell Survival - drug effects | Tumor Stem Cell Assay | Urologic Neoplasms - metabolism | DNA Modification Methylases - metabolism | Histone Deacetylases - metabolism | Workflow | Histone Demethylases - metabolism | Fluorescent Antibody Technique | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Histones - metabolism | DNA Methylation - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
by Petrylak, Daniel and Petrylak, Daniel P and de Wit, Ronald and Chi, Kim Nguyen and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Yu-Li and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor and Percent, Ivor J and Lee, Yun-Gyoo and Lee, Hyo Jin and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia Z and Safina, Sufia and